Quarterly ResultAug 4, 2026, 04:10 PM
Amgen Q2 Revenue +10% to $10.1B; GAAP EPS $4.37, Non-GAAP $6.29
AI Summary
Amgen reported strong second-quarter 2026 financial results, with total revenues increasing 10% to $10.1 billion and GAAP EPS rising 65% to $4.37. The company's six key growth drivers contributed significantly, growing 26% year-over-year. While several products like Repatha and UPLIZNA showed substantial sales growth, others such as Prolia and XGEVA experienced declines due to biosimilar competition and the Inflation Reduction Act. Amgen also provided extensive updates on its pipeline, including multiple Phase 3 studies for MariTide and regulatory discussions for TAVNEOS and BLINCYTO.
Key Highlights
- Total revenues increased 10% year-over-year to $10.1 billion.
- GAAP earnings per share (EPS) rose 65% to $4.37.
- Non-GAAP EPS increased 4% to $6.29.
- Free cash flow generated was $3.5 billion, up from $1.9 billion in Q2 2025.
- Repatha sales grew 37% to $953 million, and UPLIZNA sales surged 90% to $335 million.
- Prolia sales decreased 32% to $759 million due to biosimilar competition.
- Declared a quarterly dividend of $2.52 per share, representing a 6% increase.
- Full-year 2026 revenue guidance is $38.2 billion to $39.4 billion.
Price Impact
More from AMGN